French biomedical aesthetic company Nouveau Visage has introduced the NEWDERM regenerative microneedling system to the UK.
Nouveau Visage is entering the UK market in partnership with aesthetic distributors Fox Pharma, MedFx, Millenium and John Bannon. The company explains it is built around its patented Regen3 Complex, which combines exosomes, polydeoxyribonucleotide and biomimetic peptides in a single microneedling formulation. Nouveau Visage shares that the technology supports cellular communication, fibroblast stimulation and extracellular matrix renewal within regenerative aesthetics, aiming to aid tissue repair, collagen synthesis and improved skin structure.
According to the company, its NEWDERM range offers five targeted protocols addressing ageing, pigmentation, eye concerns, hair loss and skin laxity.
Carlos Royo, executive partner and CEO at Nouveau Visage, commented, “The UK aesthetics market continues to move rapidly towards regenerative and biologically-driven treatments, and Nouveau Visage represents a significant step forward within this space, offering an innovative and versatile treatment portfolio for discerning clinics. We are excited to be launching in the UK and adding this market to our growing list of territories – and we look forward to working closely with aesthetic practitioners, clinics and pharmacy partners to support this exciting rollout.”